Enterobacter

(Redirected from Aerobacter)

Enterobacter is a genus of common Gram-negative, facultatively anaerobic, rod-shaped, non-spore-forming bacteria of the family Enterobacteriaceae. Cultures are found in soil, water, sewage, feces and gut environments. It is the type genus of the order Enterobacterales.[1] Several strains of these bacteria are pathogenic and cause opportunistic infections in immunocompromised (usually hospitalized) hosts and in those who are on mechanical ventilation. The urinary and respiratory tracts are the most common sites of infection. The genus Enterobacter is a member of the coliform group of bacteria. It does not belong to the fecal coliforms (or thermotolerant coliforms) group of bacteria, unlike Escherichia coli, because it is incapable of growth at 44.5 °C in the presence of bile salts.[citation needed] Some of them show quorum sensing properties.[2][3]

Enterobacter
Enterobacter cloacae on trypticase soy agar
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Hormaeche & Edwards 1960
Species

E. aerogenes
E. amnigenus
E. arachidis
E. asburiae
E. bugandensis
E. cancerogenous
E. cloacae
E. cowanii
E. dissolvens
E. gergoviae
E. helveticus
E. hormaechei
E. intermedius
E. kobei
E. ludwigii
E. mori
E. nimipressuralis
E. oryzae
E. pulveris
E. pyrinus
E. radicincitans
E. taylorae
E. turicensis
E. soli

Synonyms

Cloaca Castellani & Chalmers, 1919
Aerobacter Hormaeche & Edwards, 1958

One clinically important species from this genus is E. cloacae.

Researchers in 2018 reported, after detecting the presence on the International Space Station (ISS) of five Enterobacter bugandensis bacterial strains, none pathogenic to humans, that microorganisms on ISS should be carefully monitored to continue assuring a medically healthy environment for the astronauts.[4][5]

Biochemical characteristics

edit

The genus Enterobacter ferments lactose with gas production during a 48-hour incubation at 35-37 °C in the presence of bile salts and detergents. It is oxidase-negative, indole-negative, and urease-variable.[3][6]

Virulent characteristics

edit

For Enterobacter species, the flagella is used for adhesion, biofilm formation, and protein export as well as motility. Between the strains, the microbial genus produces endotoxins unique to the species.[7]

As a gram negative bacterium, the lipopolysaccharide capsule helps to avoid phagocytosis and can initiate inflammatory response.

Symptoms

edit

In patients, pathogenic strains were found in the sputum, blood, wounds, and stool. Enterobacter is associated with common nosocomial infections including respiratory, endocarditis, bacteremia, urinary tract infections, osteomyelitis, among others.[8] Enterobacter bacteremia presents as fever but can progress to SIRS and shock.[8] For Enterobacter pneumonia, symptoms include coughing and shortness of breath.[8]

Treatment

edit

Treatment is dependent on local trends of antibiotic resistance. Enterobacter huaxiensis and Enterobacter chuandaensis are two recently discovered species that exhibit especially antibiotic resistant characteristics.[9]

Cefepime, a fourth-generation cephalosporin from the β-Lactam antibiotic class.[more detail needed] Imipenem (a carbapenem) is often the antibiotic of choice. Aminoglycosides such as amikacin have been found to be very effective, as well.[6] Quinolones can be an effective alternative.[6]

Linked to obesity

edit

A 2012 study has shown that the presence of Enterobacter cloacae B29 in the gut of a morbidly obese individual may have contributed to the patient's obesity. Reduction of the bacterial load within the patient's gut, from 35% E. cloacae B29 to non-detectable levels, was associated with a parallel reduction in endotoxin load in the patient and a concomitant, significant reduction in weight.[10] Furthermore, the same bacterial strain, isolated from the patient, induced obesity and insulin resistance in germfree C57BL/6J mice that were being fed a high-fat diet. The study concludes that E. cloacae B29 may contribute to obesity in its human hosts through an endotoxin-induced, inflammation-mediated mechanism.[10]

References

edit
  1. ^ Adeolu, M.; et al. (2016). "Genome based phylogeny and taxonomy of the 'Enterobacteriales': proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov". Int. J. Syst. Evol. Microbiol. 66 (12): 5575–5599. doi:10.1099/ijsem.0.001485. PMID 27620848.
  2. ^ Tan, Wen-Si; Muhamad Yunos, Nina Yusrina; Tan, Pui-Wan; Mohamad, Nur Izzati; Adrian, Tan-Guan-Sheng; Yin, Wai-Fong; Chan, Kok-Gan (13 June 2014). "Freshwater-Borne Bacteria Isolated from a Malaysian Rainforest Waterfall Exhibiting Quorum Sensing Properties". Sensors. 14 (6): 10527–10537. Bibcode:2014Senso..1410527T. doi:10.3390/s140610527. PMC 4118381. PMID 24932870.
  3. ^ a b Cabral, JPS (2010). "Water Microbiology. Bacterial Pathogens and Water". Int. J. Environ. Res. Public Health. 7 (10): 3657–3703. doi:10.3390/ijerph7103657. PMC 2996186. PMID 21139855.
  4. ^ BioMed Central (22 November 2018). "ISS microbes should be monitored to avoid threat to astronaut health". EurekAlert!. Retrieved 25 November 2018.
  5. ^ Singh, Nitin K.; et al. (23 November 2018). "Multi-drug resistant Enterobacter bugandensis species isolated from the International Space Station and comparative genomic analyses with human pathogenic strains". BMC Microbiology. 18 (1): 175. doi:10.1186/s12866-018-1325-2. PMC 6251167. PMID 30466389.
  6. ^ a b c Russo Thomas A, Johnson James R, "Chapter 143. Diseases Caused by Gram-Negative Enteric Bacilli" (Chapter). Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine, 17e: http://www.accessmedicine.com/content.aspx?aID=2894446.[dead link]
  7. ^ Davin-Regli, Anne; Lavigne, Jean-Philippe; Pagès, Jean-Marie (17 July 2019). "Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance". Clinical Microbiology Reviews. 32 (4): e00002-19. doi:10.1128/cmr.00002-19. PMC 6750132. PMID 31315895.
  8. ^ a b c Ramirez, Giron M. (2022). Enterobacter Infections. In: StatPearls Publishing, Treasure Island (FL). PMID 32644722.
  9. ^ Wu, Wenjing (19 October 2018). "Enterobacter huaxiensis sp. nov. and Enterobacter chuandaensis sp. nov., recovered from human blood". International Journal of Systematic and Evolutionary Microbiology. 69 (3): 708–714. doi:10.1099/ijsem.0.003207. PMID 30614784.
  10. ^ a b Fei, Na; Zhao, Liping (13 December 2012). "An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice". The ISME Journal. 7 (4): 880–4. doi:10.1038/ismej.2012.153. ISSN 1751-7362. PMC 3603399. PMID 23235292.

Davin-Regli, A., Lavigne, J. P., & Pagès, J. M. (2019). Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. Clinical microbiology reviews, 32(4), e00002-19. https://doi.org/10.1128/CMR.00002-19

edit
  NODES
orte 1